# OnCo record paper-keynote-048-lancet-2019 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-keynote-048-lancet-2019/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-keynote-048-lancet-2019" ;
  schema:name "KEYNOTE-048: pembrolizumab, alone or with chemotherapy, as first treatment for recurrent or metastatic head and neck cancer"@en ;
  schema:description "Pembrolizumab, either alone in PD-L1-positive tumours or combined with chemotherapy, helped patients with recurrent or metastatic head and neck squamous cell cancer live longer than the previous cetuximab-based standard."@en ;
  schema:url <https://onco.cc/key-papers/paper-keynote-048-lancet-2019/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://pubmed.ncbi.nlm.nih.gov/?term=KEYNOTE-048+pembrolizumab+head+and+neck+Burtness+Lancet+2019>, <https://clinicaltrials.gov/study/NCT02358031> ;
  schema:sameAs <https://doi.org/10.1016/S0140-6736(19)32591-7> ;
  schema:datePublished "2019"^^xsd:gYear ;
  schema:author "Burtness B, Harrington KJ, Greil R, et al." ;
  onco:cancers <https://onco.cc/cancers/head-and-neck/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/platinum/>, <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/egfr/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/> ;
  onco:companies <https://onco.cc/companies/merck/> ;
  onco:institutions <https://onco.cc/institutions/icr-london/>, <https://onco.cc/institutions/royal-marsden/> ;
  onco:terms <https://onco.cc/terms/cps/>, <https://onco.cc/terms/os/>, <https://onco.cc/terms/pfs/>, <https://onco.cc/terms/first-line/>, <https://onco.cc/terms/orr/> ;
  onco:people <https://onco.cc/people/kevin-harrington/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-biomarker-validation/>, <https://onco.cc/bottlenecks/b-immunotherapy-response/> ;
  onco:journals <https://onco.cc/journals/lancet/> .